ZHANG-2016-GP
Regimen
- Experimental
- Gemcitabine 1000 mg/m² d1+8 + cisplatin 80 mg/m² d1, q3w up to 6 cycles (GP)
- Control
- Fluorouracil 4000 mg/m² continuous infusion d1-96h + cisplatin 80 mg/m² d1, q3w up to 6 cycles (PF)
Population
Recurrent or metastatic NPC (treatment-naive for RM disease), no prior platinum-based chemotherapy for RM setting; enrolled at 22 Chinese centers
Key finding
Gemcitabine-cisplatin (GP) demonstrated superior PFS over the historical fluorouracil-cisplatin (PF) regimen. This established GP as the global standard first-line chemotherapy backbone for recurrent/metastatic NPC, superseding PF. All subsequent PD-1 combination trials used GP as the control arm, making this trial the foundational reference for the Chinese chemo-IO breakthrough era.
Source: PMID 27567279